Cytokinetics (CYTK) AI Stock Analysis

• Market Cap: $8.22B
• Dividend Yield: N/A
• Average Volume (3M): 1.84M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 2609.26%
• EPS Growth: -17.08%
• Country: US
• Employees: 498
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.55
• Shares Outstanding: 122,264,930
• 10 Day Avg. Volume: 2,053,867
• 30 Day Avg. Volume: 1,844,334
• PEG Ratio: 2.56
• Price to Book (P/B): -38.91
• Price to Sales (P/S): 285.13
• P/FCF Ratio: -13.18
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 78.26
• Enterprise Value/Gross Profit: -61.37
• Enterprise Value/Ebitda: -10.56
• 1Y Price Target: $79.92
• Price Target Upside: 18.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): -6.31
• Revenue Forecast (FY): $83.39M

• Rating: 58 Neutral
• Price Target: $69.00 ▲(2.66% Upside)

Cytokinetics' stock score is primarily influenced by its challenging financial performance, which is a major concern due to negative profitability and high leverage. However, strong technical indicators and positive earnings call sentiment regarding upcoming drug approvals provide some optimism. The valuation remains risky due to the lack of profitability and dividend yield.

Positive Factors

Strong Financial Position

A robust cash position provides Cytokinetics with the financial flexibility to support ongoing R&D and commercialization efforts, crucial for long-term growth.

European and Global Expansion Plans

Expanding into international markets can significantly increase Cytokinetics' revenue potential and market presence, supporting long-term growth.

MAPLE-HCM Trial Success

Successful trial results enhance the credibility and market potential of aficamten, positioning it as a strong alternative to existing therapies.

Negative Factors

Increased Net Loss

Rising net losses highlight financial challenges, potentially limiting resources for future development and impacting long-term sustainability.

Pending Regulatory Approval

Pending regulatory approvals introduce uncertainty, delaying market entry and revenue generation, which can affect strategic planning.

Financial Instability

High leverage and negative profitability can strain financial resources, limiting the company's ability to invest in growth and innovation.

Cytokinetics Business Overview & Revenue Model

Company Description

Cytokinetics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and other therapeutics to treat debilitating diseases and medical conditions that affect muscle function. The company operates primarily in the sectors of neuromuscular diseases and cardiovascular diseases, with core products that include its lead drug candidates designed to enhance muscle contractility and improve overall muscle performance.

How the Company Makes Money

Cytokinetics generates revenue primarily through collaborations and partnerships with other pharmaceutical companies, as well as potential future sales of its drug candidates upon successful commercialization. The company engages in licensing agreements, where it may receive upfront payments, milestone payments based on clinical and regulatory progress, and royalties on future product sales. Additionally, Cytokinetics may also secure funding through grants or government programs aimed at supporting innovative research in the biopharmaceutical sector. The company's partnerships with larger pharmaceutical firms can also provide significant financial support and resources, enhancing its ability to advance its drug candidates through the development pipeline.

Cytokinetics Financial Statement Overview

Summary

Cytokinetics faces significant financial challenges, with negative profitability and high leverage. Despite revenue growth, the company struggles with high costs and negative cash flows, indicating financial instability.

Income Statement

Cytokinetics has experienced significant revenue growth in recent periods, but it remains unprofitable with negative margins across the board. The gross profit margin and net profit margin are deeply negative, indicating high costs relative to revenue. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a concerning level of leverage, with a negative debt-to-equity ratio due to negative stockholders' equity. This indicates financial instability and potential risk in meeting debt obligations. The return on equity is positive but misleading due to negative equity, and the equity ratio is not favorable.

Cash Flow

Cytokinetics has negative operating and free cash flows, although there is some growth in free cash flow. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	87.21M	18.47M	7.53M	94.59M	70.43M	55.83M
Gross Profit	-111.22M	-320.93M	-322.59M	-146.22M	-89.51M	-41.12M
EBITDA	-646.17M	-493.48M	-456.68M	-329.40M	-176.34M	-86.78M
Net Income	-751.94M	-589.53M	-526.24M	-388.95M	-215.31M	-127.29M
Balance Sheet
Total Assets	1.44B	1.40B	824.32M	1.01B	841.32M	533.80M
Cash, Cash Equivalents and Short-Term Investments	962.53M	1.08B	614.82M	782.58M	471.64M	464.06M
Total Debt	1.20B	788.68M	755.77M	750.30M	269.93M	138.94M
Total Liabilities	1.96B	1.54B	1.21B	1.12B	597.46M	420.42M
Stockholders Equity	-521.12M	-135.37M	-386.32M	-107.90M	243.86M	113.38M
Cash Flow
Free Cash Flow	-453.38M	-399.80M	-415.75M	-310.85M	-191.39M	-2.11M
Operating Cash Flow	-432.93M	-395.89M	-414.33M	-299.52M	-142.52M	8.94M
Investing Cash Flow	198.72M	-553.10M	239.25M	-262.13M	-147.78M	-196.51M
Financing Cash Flow	416.14M	930.61M	221.32M	516.17M	319.98M	234.12M

Cytokinetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 67.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTK, the sentiment is Positive. The current price of 67.21 is above the 20-day moving average (MA) of 63.77, above the 50-day MA of 59.09, and above the 200-day MA of 43.84, indicating a bullish trend. The MACD of 2.26 indicates Negative momentum. The RSI at 64.48 is Neutral, neither overbought nor oversold. The STOCH value of 78.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYTK.

Cytokinetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CYTK	58 Neutral	$8.22B	―	―	―	2609.26%	-17.08%
RNA	56 Neutral	$10.73B	―	-32.44%	―	106.27%	-43.90%
AXSM	55 Neutral	$7.62B	―	-275.50%	―	65.83%	28.50%
RYTM	52 Neutral	$7.11B	―	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	47 Neutral	$5.01B	―	-22.60%	―	74.91%	31.54%
NUVL	43 Neutral	$7.96B	―	-38.79%	―	―	-52.84%

Cytokinetics Corporate Events

Cytokinetics’ Earnings Call: Progress and Challenges

Cytokinetics’ recent earnings call conveyed a mixed sentiment, highlighting both significant achievements and challenges. The company is making notable strides towards the approval and commercial readiness of aficamten, backed by impressive clinical trial outcomes and a robust financial standing. However, the increased net loss and pending regulatory approvals pose substantial hurdles.

Cytokinetics’ Q3 2025: Progress in Cardiac Therapies

Cytokinetics, Incorporated is a biopharmaceutical company specializing in cardiovascular treatments, focusing on muscle biology to develop potential new medicines for cardiac muscle dysfunction. In its third-quarter 2025 earnings report, Cytokinetics highlighted its ongoing preparations for the potential commercialization of aficamten, a cardiac myosin inhibitor, with regulatory reviews progressing in the U.S., China, and the EU. The company reported $1.25 billion in cash and investments, a significant increase from the previous quarter, and continued its strategic focus on advancing its cardiac muscle programs.

Cytokinetics Discusses Aficamten with FDA in Late Cycle Meeting

On September 15, 2025, Cytokinetics participated in a Late Cycle Meeting with the FDA regarding its New Drug Application for aficamten, aimed at treating obstructive hypertrophic cardiomyopathy. The company discussed its Risk Evaluation and Mitigation Strategies (REMS) and anticipates a differentiated label for aficamten, pending FDA approval by December 26, 2025. Additionally, Cytokinetics responded to the European Medicines Agency’s questions about aficamten’s potential EU approval. The company plans to draw $100 million from a loan agreement with Royalty Pharma by October 1, 2025, to support its development efforts.

The most recent analyst rating on (CYTK) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.

Cytokinetics’ COMET-HF Study: A Potential Game-Changer for Heart Failure Treatment?

Study Overview: The COMET-HF study, officially titled A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction, aims to evaluate whether the investigational drug omecamtiv mecarbil can reduce the risk of heart failure-related events such as hospitalization, transplantation, or death in patients with severely reduced ejection fraction.

Cytokinetics’ Aficamten Study: A Potential Breakthrough for Pediatric Heart Conditions

Study Overview: Cytokinetics is conducting a study titled ‘A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy.’ The study aims to assess the efficacy and safety of aficamten in children with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition that affects heart muscle function. This research is significant as it targets a pediatric population, addressing a critical need for effective treatments in this demographic.

Cytokinetics Highlights Aficamten Data at ESC Congress

On August 31, 2025, Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting its efficacy in improving cardiac structure and function compared to metoprolol in patients with hypertrophic cardiomyopathy (HCM). The data, published in the Journal of the American College of Cardiology and Heart Rhythm, also showed that aficamten has a low incidence of atrial fibrillation and maintains a consistent safety profile, reinforcing its potential as a treatment option under FDA review.

The most recent analyst rating on (CYTK) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.

Cytokinetics Reveals Promising MAPLE-HCM Trial Results

Cytokinetics announced the results of its MAPLE-HCM trial, presented at the European Society of Cardiology Congress 2025, showing that aficamten outperformed the standard beta-blocker metoprolol in improving exercise capacity in patients with obstructive hypertrophic cardiomyopathy (oHCM). The trial results suggest a potential shift in treatment practices, as aficamten demonstrated superior efficacy across primary and secondary endpoints, including improved functional class and reduced symptom burden, compared to metoprolol. These findings could significantly impact the company’s market positioning and offer new treatment options for oHCM patients.

The most recent analyst rating on (CYTK) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.

Cytokinetics Appoints James M. Daly to Board

On August 19, 2025, Cytokinetics appointed James M. Daly to its Board of Directors as a Class III member, with his term expiring in 2028. Mr. Daly, determined to be independent under corporate governance guidelines, will also serve on the Compliance Committee and participate in the company’s non-employee director compensation arrangements, including stock options and restricted stock units.

The most recent analyst rating on (CYTK) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.

Cytokinetics’ Aficamten Study: A Potential Breakthrough for Pediatric Heart Health

Study Overview: Cytokinetics is conducting a study titled A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy. The study aims to assess the efficacy, safety, and pharmacokinetics of aficamten in children and adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition that can severely impact heart function. This trial is significant as it targets a pediatric population, potentially offering a new treatment avenue for young patients.

Cytokinetics’ Earnings Call: Progress Amid Challenges

Cytokinetics’ recent earnings call presented a mixed sentiment, highlighting significant strides in regulatory achievements and commercial preparations, particularly for their lead drug, aficamten. The company expressed optimism about upcoming approvals and market launches, yet acknowledged the challenges posed by increased expenses, net losses, and an extended PDUFA date.